CClinicalTrials.gg
CompletedNCT03647150Hi-MAMUpdated Sep 1, 2020

Treatment of High-Risk Moderate Acute Malnutrition Using Expanded Admission Criteria

An interventional study of amoxicillin and Ready-to-use therapeutic food (RUTF) in Malnutrition, sponsored by Washington University School of Medicine. Completed at 1 site in Sierra Leone. Open to participants aged 6 Months to 59 Months. Per ClinicalTrials.gov, last updated 2020-09-01.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
1,322
Allocation
Randomized
Ages
6 Months to 59 Months
Sex
All
01

Study summary

This project explores whether children have better growth and cognitive development when the clinic identifies "higher risk" MAM children and support them either with the same treatment as SAM children or with the recommended practice: nutrition counseling.

Read the detailed description

This is a cluster-randomized controlled trial taking place in 20 community clinics providing malnutrition care in Sierra Leone.

All participants will be children aged 6-59 months. Control participants will have moderate acute malnutrition (MAM), defined as mid-upper arm circumference (MUAC) 11.5-\<12.5. High Risk MAM will be defined with a MUAC 11.5 to \<11.9 or WAZ\<-3.5 or Mother not the caretaker or not breastfeeding at \<2 years old. Low risk MAM defined with a MUAC 11.9 to \<12.5 with no risk factors.

Control group and low risk group caregiver's will received nutrition education via mother care groups every two weeks for 6 weeks and will be followed up 12 and 24 weeks post-enrollment.

High risk group will receive 1 week supply of amoxicillin at enrollment and 1 sachet of RUTF per day till MUAC is equal to or greater than 12.5 or up to 12 weeks of treatment. Their caregiver will also receive nutrition education via the mother care groups. The investigators will also follow up with the participant at 12 and 24 weeks post-enrollment.

A subset of the participants in each group will also be enrolled in a cognitive development substudy were the investigators will be using a eye tracking performance assessment. Investigators will also enroll health adult participants for eye tracking assessment. Adult data will be used as a reference when interpreting results.

02

Conditions studied

  • Malnutrition

Browse trials for

03

Who can participate

Ages eligible
6 Months to 59 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • uncomplicated MAM (based on MUAC equal to or greater than 11.5 cm and \<12.5)

Exclusion criteria

Exclusion Criteria:

  • currently involved in another research trial or feeding program
  • medical complication such as oedema, severe nausea/vomiting, severe dehydration, or severe pneumonia
  • have a diagnosed or visible sign of developmental delay
  • have a history of peanut or milk allergy
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,322 participants (actual)

Study arms

  • Other
    Moderate Acute Malnutrition (MAM)

    MAM children at control clinics or MAM children at intervention clinics that do no have high rick characteristics. Control treatment is "Mother Care" counselling, delivered by a respected elder in the local community.

    Behavioral: Mother Care group

  • Experimental
    High Risk Moderate Acute Malnutrition (MAM)

    The intervention treatment incorporates Mother Care counselling, provision of one packet (508 calories) of ready-to-use therapeutic food (RUTF) daily and a 1 week course of amoxicillin. This provision will continue until the child has reached a mid-upper arm circumference (MUAC) equal to or greater than 12.5 cm or 12 weeks have elapsed.

    Drug: amoxicillin · Dietary Supplement: Ready-to-use therapeutic food (RUTF) · Behavioral: Mother Care group

Interventions

  • Drugamoxicillin

    At enrollment the child will receive a 1 week course of amoxicillin

  • Dietary supplementReady-to-use therapeutic food (RUTF)

    1 sachet RUTF per day (508 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed

  • BehavioralMother Care group

    Nutrition education via mother care groups lead by a respected elder in the local community

05

What researchers measure

Primary outcomes

  1. Recovery from moderate acute malnutrition (MAM)

    proportion of participants recovered based on mid-upper arm circumference(MUAC) Recovery is defined as MUAC greater than or equal to 12.5cm before or at 12 weeks after enrollment.

    Time frame: up to 12 weeks of treatment

Secondary outcomes

  1. Participant survival rates

    Proportion of participants survival rates during the study

    Time frame: Duration of the study 24 weeks post-enrollment

  2. Participants deterioration to severe acute malnutrition(SAM)

    Proportion of participants that deteriorate from moderate acute malnutrition(MAM) to severe acute malnutrition(SAM). SAM is defined at mid-upper arm circumference(MUAC)\<11.5 or presence of oedema.

    Time frame: Duration of the study 24 weeks post-enrollment

  3. Participants that remain or become underweight using weight for age z-score

    the difference between the weight for age z-score(WAZ) from enrollment to 24 weeks post-enrollment

    Time frame: 24 weeks post-enrollment

  4. Participants that remain or become Stunted

    the difference between length for age z-score(LAZ) from enrollment to 24 weeks post enrollment

    Time frame: 24 weeks post-enrollment

  5. Participants that remain or become Wasted

    the difference between weight for length z-score(WHL) from enrollment to 24 weeks post enrollment

    Time frame: 24 weeks post-enrollment

  6. Eye tracking performance for cognitive development

    the difference between the eye tracking performance from enrollment to 24 weeks post enrollment

    Time frame: 24 weeks post enrollment

06

Study locations

1 site
  • Project Peanut Butter
    Freetown, Sierra Leone
07

References and documents

Publications

  • Joshua GE, Jadhav M, Bhaktaviziam A, Mokashi S. Mental retardation in children. II. Leucodystrophies. Indian Pediatr. 1974 Jan;11(1):53-9. No abstract available. PubMed 4839581 ↗
  • Lenters LM, Wazny K, Webb P, Ahmed T, Bhutta ZA. Treatment of severe and moderate acute malnutrition in low- and middle-income settings: a systematic review, meta-analysis and Delphi process. BMC Public Health. 2013;13 Suppl 3(Suppl 3):S23. doi: 10.1186/1471-2458-13-S3-S23. Epub 2013 Sep 17. PubMed 24564235 ↗
  • Chang CY, Trehan I, Wang RJ, Thakwalakwa C, Maleta K, Deitchler M, Manary MJ. Children successfully treated for moderate acute malnutrition remain at risk for malnutrition and death in the subsequent year after recovery. J Nutr. 2013 Feb;143(2):215-20. doi: 10.3945/jn.112.168047. Epub 2012 Dec 19. PubMed 23256140 ↗
  • Maust A, Koroma AS, Abla C, Molokwu N, Ryan KN, Singh L, Manary MJ. Severe and Moderate Acute Malnutrition Can Be Successfully Managed with an Integrated Protocol in Sierra Leone. J Nutr. 2015 Nov;145(11):2604-9. doi: 10.3945/jn.115.214957. Epub 2015 Sep 30. PubMed 26423737 ↗
  • Ekelund U, Ong KK, Linne Y, Neovius M, Brage S, Dunger DB, Wareham NJ, Rossner S. Association of weight gain in infancy and early childhood with metabolic risk in young adults. J Clin Endocrinol Metab. 2007 Jan;92(1):98-103. doi: 10.1210/jc.2006-1071. Epub 2006 Oct 10. PubMed 17032722 ↗
  • Khara T, Mwangome M, Ngari M, Dolan C. Children concurrently wasted and stunted: A meta-analysis of prevalence data of children 6-59 months from 84 countries. Matern Child Nutr. 2018 Apr;14(2):e12516. doi: 10.1111/mcn.12516. Epub 2017 Sep 25. PubMed 28944990 ↗
  • Schofield C, Ashworth A. Why have mortality rates for severe malnutrition remained so high? Bull World Health Organ. 1996;74(2):223-9. PubMed 8706239 ↗
  • Lelijveld N, Godbout C, Krietemeyer D, Los A, Wegner D, Hendrixson DT, Bandsma R, Koroma A, Manary M. Treating high-risk moderate acute malnutrition using therapeutic food compared with nutrition counseling (Hi-MAM Study): a cluster-randomized controlled trial. Am J Clin Nutr. 2021 Sep 1;114(3):955-964. doi: 10.1093/ajcn/nqab137. PubMed 33963734 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03647150
Lead sponsor
Washington University School of Medicine
Collaborators
Centre for Global Child Health, Hospital for Sick Kids, Toronto, Canada, Department of Psychology, University of Tampere, Finland, Project Peanut Butter, Sierra Leone
Responsible party
Sponsor
First posted
Aug 27, 2018
Start date
Nov 13, 2018
Primary completion
Jun 5, 2020
Completion
Jun 5, 2020
Last update
Sep 1, 2020

Study contacts

Mark Manary, MD
principal investigator · Washington University School of Medicine in St. Louis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion